A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer

Hepatocellular carcinoma (HCC) is widespread cancer with a high degree of morbidity and mortality in individuals worldwide and a serious concern for its resistance to present chemotherapy drugs. In this investigation, the combination of cisplatin (CPT) and metformin (MET) to kill the HepG2 and caco-...

Full description

Bibliographic Details
Main Authors: Zhiyuan Zhang, Tianhao Su, Yanjing Han, Zeran Yang, Jian Wei, Long Jin, Haining Fan
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Drug Delivery
Subjects:
Online Access:http://dx.doi.org/10.1080/10717544.2021.1974606
id doaj-a41ed691df3f4ec29b5bb08edeb87f91
record_format Article
spelling doaj-a41ed691df3f4ec29b5bb08edeb87f912021-10-04T13:57:00ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642021-01-012811982199410.1080/10717544.2021.19746061974606A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancerZhiyuan Zhang0Tianhao Su1Yanjing Han2Zeran Yang3Jian Wei4Long Jin5Haining Fan6Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical UniversityDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical UniversityDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical UniversityDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical UniversityDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical UniversityDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical UniversityDepartment of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai UniversityHepatocellular carcinoma (HCC) is widespread cancer with a high degree of morbidity and mortality in individuals worldwide and a serious concern for its resistance to present chemotherapy drugs. In this investigation, the combination of cisplatin (CPT) and metformin (MET) to kill the HepG2 and caco-2 cells was developed into a new pH-responding magnetic nanocomposite based on reduced graphene oxide. Polyhydroxyethyl methacrylic (PHEA) was then linked employing grafting from approach to the reduced graphene oxide by ATRP polymerization (Fe3O4@rGO-G-PSEA). FT-IR, SEM, XRD, DLS, and TGA analyses evaluated physicochemical characteristics of the nanocomposite. In addition, the cellular uptake property of the nanocomposites was examined by the HepG2 cells. The outcomes of cell viability results indicate that the nanoparticles loaded with MET&CPT showed the lowest concentration rate of HepG2 and Caco-2 cells compared to the drug-loaded single nanocomposite groups and free drugs. The histological analysis has demonstrated relatively safe and does not produce different stress such as swelling and inflammation of the mice organs. Our results show the enhancement in cytotoxicity in HepG2 and Cocoa-2 cells by MET and CPT graphene oxide-based nanocomposite by promoting apoptotic response. Moreover, Fe3O4@rGO-G-PSEA showed potent in vivo antitumor efficacy but showed no adverse toxicity to normal tissues. Together, this study can provide insight into how surface embellishment may tune these nanocomposites' tumor specificity and provide the basis for developing anticancer efficacy.http://dx.doi.org/10.1080/10717544.2021.1974606combination drugsgraphenehepatocellular carcinomaapoptosisin vivo animal model
collection DOAJ
language English
format Article
sources DOAJ
author Zhiyuan Zhang
Tianhao Su
Yanjing Han
Zeran Yang
Jian Wei
Long Jin
Haining Fan
spellingShingle Zhiyuan Zhang
Tianhao Su
Yanjing Han
Zeran Yang
Jian Wei
Long Jin
Haining Fan
A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
Drug Delivery
combination drugs
graphene
hepatocellular carcinoma
apoptosis
in vivo animal model
author_facet Zhiyuan Zhang
Tianhao Su
Yanjing Han
Zeran Yang
Jian Wei
Long Jin
Haining Fan
author_sort Zhiyuan Zhang
title A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
title_short A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
title_full A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
title_fullStr A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
title_full_unstemmed A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
title_sort convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer
publisher Taylor & Francis Group
series Drug Delivery
issn 1071-7544
1521-0464
publishDate 2021-01-01
description Hepatocellular carcinoma (HCC) is widespread cancer with a high degree of morbidity and mortality in individuals worldwide and a serious concern for its resistance to present chemotherapy drugs. In this investigation, the combination of cisplatin (CPT) and metformin (MET) to kill the HepG2 and caco-2 cells was developed into a new pH-responding magnetic nanocomposite based on reduced graphene oxide. Polyhydroxyethyl methacrylic (PHEA) was then linked employing grafting from approach to the reduced graphene oxide by ATRP polymerization (Fe3O4@rGO-G-PSEA). FT-IR, SEM, XRD, DLS, and TGA analyses evaluated physicochemical characteristics of the nanocomposite. In addition, the cellular uptake property of the nanocomposites was examined by the HepG2 cells. The outcomes of cell viability results indicate that the nanoparticles loaded with MET&CPT showed the lowest concentration rate of HepG2 and Caco-2 cells compared to the drug-loaded single nanocomposite groups and free drugs. The histological analysis has demonstrated relatively safe and does not produce different stress such as swelling and inflammation of the mice organs. Our results show the enhancement in cytotoxicity in HepG2 and Cocoa-2 cells by MET and CPT graphene oxide-based nanocomposite by promoting apoptotic response. Moreover, Fe3O4@rGO-G-PSEA showed potent in vivo antitumor efficacy but showed no adverse toxicity to normal tissues. Together, this study can provide insight into how surface embellishment may tune these nanocomposites' tumor specificity and provide the basis for developing anticancer efficacy.
topic combination drugs
graphene
hepatocellular carcinoma
apoptosis
in vivo animal model
url http://dx.doi.org/10.1080/10717544.2021.1974606
work_keys_str_mv AT zhiyuanzhang aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT tianhaosu aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT yanjinghan aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT zeranyang aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT jianwei aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT longjin aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT hainingfan aconvergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT zhiyuanzhang convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT tianhaosu convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT yanjinghan convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT zeranyang convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT jianwei convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT longjin convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
AT hainingfan convergentsyntheticplatformfordualanticancerdrugsfunctionalizedbyreducedgraphenenanocompositedeliveryforhepatocellularcancer
_version_ 1716844071887044608